Table 3.
Fatty acid profile (%) in postmortem brain tissue of Alzheimer’s disease patients and control subjects.
| Fatty Acid (%) Respect to Total Fatty Acid Content | Control (n = 11) | GDS6 (n = 11) | p |
|---|---|---|---|
| Lauric acid (12:0) | 0.08 ± 0.02 | 0.05 ± 0.01 | 0.159 |
| Palmitic acid (16:0) | 20.00 ± 0.55 | 20.19 ± 1.00 | 0.864 |
| Hexadecanoic acid (16:1 n-9) | 0.52 ± 0.03 | 0.59 ± 0.06 | 0.342 |
| Palmitoleic acid (16:1 n-7) | 0.65 ± 0.04 | 0.56 ± 0.04 | 0.141 |
| Margaric acid (17:0) | 0.30 ± 0.01 | 0.31 ± 0.01 | 0.428 |
| Stearic acid (18:0) | 20.55 ± 0.29 | 19.99 ± 0.30 | 0.201 |
| Elaidic acid (18:1 trans) | 0.05 ± 0.01 | 0.05 ± 0.01 | 0.911 |
| Oleic acid (18:1 n-9) | 17.58 ± 0.68 | 18.44 ± 1.08 | 0.496 |
| Cis-vaccenic acid (18:1 n-7) | 4.15 ± 0.21 | 4.37 ± 0.21 | 0.462 |
| Linoelaidic acid (18:2 all trans-9,12) | 0.01 ± 0.01 | 0.00 ± 0.00 | 0.374 |
| Linoelaidic acid (18:2 trans-12) | 0.03 ± 0.03 | 0.00 ± 0.00 | 0.374 |
| Linoleic acid (18:2 n-6) | 0.86 ± 0.09 | 0.76 ± 0.12 | 0.478 |
| α-linolenic acid (18:3 n-3) | 0.34 ± 0.04 | 0.34 ± 0.06 | 0.960 |
| Arachidic acid (20:0) | 0.27 ± 0.01 | 0.27 ± 0.02 | 0.923 |
| Gondoic acid (20:1 n-9) | 0.79 ± 0.10 | 0.89 ± 0.16 | 0.568 |
| Eicosadienoic acid (20:2 n-6) | 0.23 ± 0.02 | 0.29 ± 0.02 | 0.075 |
| Dihomo-γ-linolenic acid (20:3 n-6) | 1.08 ± 0.07 | 1.03 ± 0.08 | 0.623 |
| Eicosatrienoic acid (20:3 n-3) | 0.02 ± 0.02 | 0.00 ± 0.00 | 0.374 |
| Arachidonic acid (20:4 n-6, AA) | 8.83 ± 0.35 | 8.60 ± 0.48 | 0.697 |
| Eicosapentaenoic acid (20:5 n-3, EPA) | 0.05 ± 0.04 | 0.00 ± 0.00 | 0.174 |
| Behenic acid (22:0) | 0.48 ± 0.08 | 0.65 ± 0.08 | 0.159 |
| Erucic acid (22:1 n-9) | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.073 |
| Adrenic acid (22:4 n-6) | 4.78 ± 0.14 | 4.32 ± 0.17 | 0.051 |
| Docosapentaenoic acid (22:5 n-6, DPA) | 1.23 ± 0.10 | 1.89 ± 0.23* | 0.022 |
| Docosapentaenoic acid (22:5 n-3) | 0.41 ± 0.07 | 0.26 ± 0.03 | 0.079 |
| Docosahexaenoic acid (22:6 n-3, DHA) | 11.83 ± 0.80 | 10.77 ± 1.20 | 0.458 |
| Tricosylic acid (23:0) | 0.14 ± 0.07 | 0.10 ± 0.06 | 0.679 |
| Lignoceric acid (24:0) | 1.05 ± 0.16 | 1.20 ± 0.29 | 0.653 |
| Nervonic acid (24:1 n-9) | 3.63 ± 0.53 | 4.00 ± 0.98 | 0.734 |
| SFA | 42.88 ± 0.47 | 42.77 ± 0.79 | 0.903 |
| MUFA | 27.37 ± 1.32 | 28.93 ± 2.12 | 0.525 |
| PUFA | 29.67 ± 0.94 | 28.26 ± 1.41 | 0.402 |
| TRANS | 0.09 ± 0.04 | 0.05 ± 0.01 | 0.349 |
| PUFA n-6 | 17.02 ± 0.37 | 16.89 ± 0.51 | 0.832 |
| PUFA n-3 | 12.65 ± 0.78 | 11.37 ± 1.14 | 0.355 |
| n-6/n-3 | 1.44 ± 0.15 | 1.69 ± 0.27 | 0.410 |
| LC-PUFA n-6 | 16.16 ± 0.33 | 16.13 ± 0.53 | 0.966 |
| LC-PUFA n-3 | 12.31 ± 0.82 | 11.03 ± 1.19 | 0.374 |
| Total Fatty Acid concentration (mg/g) | 23.82 ± 1.09 | 22.37 ± 1.62 | 0.454 |
AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LC-PUFA, long-chain polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; TRANS, trans fatty acids. Mean ± SEM. Significant differences are indicated by footnote symbols: * Result indicates a significant difference compared to the control group (p < 0.05) (bold face).